Winning Stock Forecast: Celsion Corp. (NASDAQ: CLSN) Gained Nearly 30% Up Move For Promising Research Pipeline

Winning Stock Forecast

“Celsion continues to make significant progress with our two ongoing clinical development programs for ThermoDox® and GEN-1.  With sound fundamentals and a strong balance sheet, we are well positioned to complete enrollment in our ongoing 550 patient global, pivotal Phase III OPTIMA Study in primary liver cancer and to initiate our 130 patient Phase I/II randomized OVATION II Study in newly diagnosed patients with ovarian cancer in June 2018 and reporting clinical findings from the Phase I cohort of 12 patients of the OVATION II by the end of 2018.” -Michael H. Tardugno, chairman

Read More

Winning ELGX Stock Forecast: Endologix Ends May With More Than 30% Gains

Our top-line performance during the first quarter reflects slightly better-than-expected growth in our OUS business driven by solid AFX growth in both the European and CAPLA markets…These accomplishments reinforce Endologix’s value proposition and our commitment to delivering the best products to physicians and patients around the globe.”

– Vaseem Mahbob, CFO of Endologix

(Source: PxHere)

Over the past 30 days, Endologix, Inc. (NASDAQ: ELGX) has been steadily climbing. Endologix, develops, produces

Read More

Quick Win by the Algorithm: IMGN Inducing Optimism

Quick Win By The Algorithm: BCRX On The Rise

Gilead Sciences Stock Forecast: Continue Buying This Top Pharmaceutical Stock (GILD)

I Know First published a bullish article on Gilead Sciences, a biopharmaceutical company with specialties addressing HIV and Hepatitis C, on Seeking Alpha. Having explained how I Know First’s algorithm works and providing an example of its success in the past, it is worthwhile to see if the algorithm agrees with the bullish fundamental analysis of the company. The three-month and one-year forecasts for Gilead Sciences are included. gilead sciences stock forecast